Search Options Stock News and Analysis from Schaeffer's

Sage Therapeutics Stock Headed for Best Day in 5 Years

https://www.schaeffersresearch.com/content/news/2025/01/13/sage-therapeutics-stock-headed-for-best-day-in-5-years

1/13/2025 11:16 AM

Biotech stock Sage Therapeutics Inc (NASDAQ:SAGE) is skyrocketing today, up 33.7% to trade at $7.42 at last glance, after Biogen's (BIIB) proposed takeover, which the company said on Friday it would...

2 Well-Priced Stocks Staging Big Swings Today

https://www.schaeffersresearch.com/content/news/2024/04/17/2-well-priced-stocks-staging-big-swings-today

4/17/2024 3:11 PM

Depending on who you ask, a recession is either right around the corner or the stock market is ready to rattle off a seismic bull run. As always, the answer is likely somewhere in the middle of those ...

2 Biotech Stocks Staging Large Swings

https://www.schaeffersresearch.com/content/options/2023/08/07/2-biotech-stocks-staging-large-swings

8/7/2023 2:32 PM

Sage Therapeutics Inc (NASDAQ:SAGE) is crumbling to record lows today, down 52.2% at $17.25 at last check, earlier hitting a low of $16.69. The U.S. Food & Drug Administration (FDA) approved its drug...

Biotech Stock Moves Higher After Fast-Track Designation

https://www.schaeffersresearch.com/content/news/2021/09/15/biotech-stock-moves-higher-after-fast-track-designation

9/15/2021 1:36 PM

SAGE Therapeutics Inc (NYSE:SAGE) is in the spotlight today, after the drugmaker received fast-track designation from the U.S. Food and Drug Administration (FDA) for its potential Huntington's diseas...

SAGE Plummets After Drug Trial Results

https://www.schaeffersresearch.com/content/news/2021/06/15/sage-plummets-after-drug-trial-results

6/15/2021 11:07 AM

The shares of Sage Therapeutics Inc (NASDAQ:SAGE) are down 16.5% to trade at $60.85 at last check, following lackluster Phase 3 test results for the biotechnology company's depression drug, Zuranolon...

PEOPLE ALSO SEARCH FOR

-intraday-options-activity